{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-011984","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.907035+00:00","generated_at":"2026-05-31T09:44:12.862106+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NeuroBo completes SAD Part 1 enrollment for obesity drug DA-1726; no issues, top-line data Q3 2024","bullets":["45 participants enrolled across 5 cohorts in SAD Part 1 of Phase 1 trial for DA-1726 (GLP1R/GCGR dual agonist).","No significant issues; accelerated start to MAD Part 2 dosing began June 2024.","Top-line SAD data expected Q3 2024; MAD top-line data Q1 2025.","Pre-clinical data showed superior weight loss vs semaglutide and survodutide, comparable to tirzepatide.","Part 3 IND update planned; first patient dosing Q3 2025, interim data mid-2026, top-line H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-011984","json":"https://secwatch.observer/filing/0001558370-24-011984.json","markdown":"https://secwatch.observer/filing/0001558370-24-011984.md","text":"https://secwatch.observer/filing/0001558370-24-011984.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024011984/0001558370-24-011984-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024011984/nrbo-20240813x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:44:12.862106+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}